Heart check for new Weight-Loss drug: survodutide under scrutiny
NCT ID NCT06200467
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study checks whether survodutide, a new weight-loss injection, affects heart rhythm in 110 overweight or obese adults. Participants receive survodutide or placebo for about 30 weeks, with heart tests before and after. The goal is to see if the drug is safe for the heart, not to measure weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
survodutide (BI 456906)
What this could lead to
If it works, this could help ensure that survodutide is safe for the heart, supporting its development as a weight-loss treatment.
What could go wrong
This is an early Phase 1 safety study, not designed to prove weight loss. The results may not predict real-world outcomes, and heart effects are still possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.